Healthcare / BiotechnologyTaipei Exchange
$19.15
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-2.9M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$925M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.8%
↓Gross Margin
48.5%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.2%
FCF CAGR
—
FCF margin
-64.0%
FCF / Net income
1.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $176.8M · net income $-92.3M · FCF $-113.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $176.8M | $176.8M | $224.3M | $160.1M | $228.6M |
| Net Income | $-92.3M | $-92.3M | $897000.00 | $10.1M | $30.0M |
| EBITDA | $-90.4M | $-90.4M | $7.5M | $20.4M | $41.0M |
| EPS | — | — | 0.02 | 0.20 | 0.54 |
| Gross Margin | 48.5% | 48.5% | 53.6% | 54.6% | 56.8% |
| Operating Margin | -60.5% | -60.5% | -5.4% | 2.1% | 11.5% |
| Net Margin | -52.2% | -52.2% | 0.4% | 6.3% | 13.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 |
| Current Ratio | 11.89 | 11.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-113.1M | $-113.1M | $-2.9M | $61.6M | $13.7M |
| Returns | |||||
| ROE | -14.8% | -14.8% | 0.1% | 1.6% | 4.7% |
| Valuation | |||||
| P/E | — | — | 1262.50 | 130.00 | 72.76 |
| EV/EBITDA | — | — | 126.33 | 58.64 | 51.28 |
| P/B | 1.48 | 1.48 | 1.70 | 2.05 | 3.42 |
| Growth & Yield | |||||
| Revenue Growth | -21.2% | -21.2% | 40.1% | -29.9% | — |
| EPS Growth | — | — | -90.0% | -62.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.02 → n/d
Residual
-3.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.